CLAIMS

1. Use of a microporous zirconium silicate potassium-binding agent in the manufacture of a medicament for treatment of hyperkalemia in a hemodialysis patient, wherein the potassium-binding agent is to be administered to the patient in need thereof.

2. The use of claim 1, where the potassium-binding agent is ~~a microporous zirconium silicate~~Sodium Zirconium Cyclosilicate.

3. The use of claim 1~~, where the potassium-binding agent is Sodium Zirconium Cyclosilicate.~~ or 2~~4. The use of claim 1~~, where the potassium-binding agent is to be administered on non-dialysis days.

4. The use of claim 2~~5. The use of claim 3~~, where the potassium-binding agent is to be administered in a 5 gram dose.

~~6. The use of claim 3~~5. The use of claim 2, where the potassium-binding agent is to be administered in a 10 gram dose.

~~7~~6. The use of claim ~~3~~2, where the potassium-binding agent is to be administered in a 15 gram dose.

~~8. The use of claim 1, where the potassium-binding agent is to be administered on non-dialysis days.~~

~~9. The use of claim 1, where the potassium-binding agent is a 2-fluoroacrylate-divinylbenzene-1,7-octadiene copolymer crosslinked in the salt or acid form.~~

~~10. The use of claim 1, where the 2-fluoroacrylate-divinylbenzene-1,7-octadiene copolymer crosslinked in the salt or acid form is patiromer sorbitex calcium.~~